IRICoR Announces Appointment of two New Directors

Montréal, Canada – December 17, 2012: Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR), is pleased to announce the appointment of the following Directors to its Board, Dr. Francine Décary and Mr. Peter Duffield.

The two new Directors officially appointed on September 27, 2012 will join today’s meeting of the IRICoR Board of Directors. Both Dr. Francine Décary and Mr. Duffield have been specifically recruited for their knowledge of life sciences industry.

Ms. Johane Boucher-Champagne, Chair of IRICoR’s Board of Directors commented, “We are delighted to have these two talented Senior Executives join our Board of Directors and assist IRICoR in its mandate to accelerate the discovery and commercialization of new innovative therapeutics in oncology and related indications through strong partnerships with Industry.

Biographies

Dr. Francine Décary has been President and Chief Executive Officer of Héma-Québec since her founding in 1998. With her team, she has managed to rank her young organization among the safe and reliable transfusioncentres of the world.

She completed her medical degree magna cum laude at the Université de Montréal (1967), her hematology in 1974 and earned a PhD in immunohematology from the University of Amsterdam (1977). She also holds an MBA from the Université de Sherbrooke (1996). A researcher and expert on the safety of blood components, she has written numerous abstracts and articles and she is a much sought-after lecturer.

Her managerial skills have been widely recognized and she has been the recipient of several distinctive awards among which, in 2002, the Ortho Award in Transfusion Medicine from the Canadian Society for Transfusion Medicine (CSTM) in recognition of her contribution to the Canadian blood system; in 2004 the YWCA Montreal Woman of Distinction Award; in 2005, the Armand-Frappier Prize representing the highest distinction of the Government of Quebec for the development and promotion of research and recently, in 2006, she was honored by the Faculty of Business Administration of the Université de Sherbrooke as “Ambassador of the university”.

Dr. Décary is a member of several boards of directors in the academic and not-for-profit sectors. Her experience, her skills and her expertise benefit the organizations for which she devotes her attention.

Mr. Peter Duffield received a Bachelor of Chemical Engineering from McGill University in 1959. He spent 23 years working for Dupont Canada in a variety of positions culminating as Operations Vice President for the Fibres Group, a third of the company.

Since 1983 he has been a consultant with his own company, has run other companies in a variety of industrial sectors and has been on the board of a number of large companies as well as cultural and community organizations.

Mr. Duffield, a former city councilor of Westmount, is currently Chair of the McGill University Health Centre Foundation’s Human Resources Committee.

About IRICoR | Institute for Research in Immunology and Cancer – Commercialization of Research
IRICoR is a non-profit organization whose mandate is to accelerate the discovery, development and commercialization of novel drugs that originate from IRIC and Université de Montréal. IRICoR, as a Center of Excellence in Commercialization and Research, invests in highly innovative projects to rapidly transition them from academia to the market, while identifying the best development partners for these commercially-promising projects. For more information about IRICoR, please visit : www.iricor.ca.

Information
IRICoR
T +1 514 343.6111 ext: 0914

© 2008-2020 IRICoR